Clinical trial
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
NCT00072449 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00072449 |
|---|---|
| Title | Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma |
| Official title | A Phase II Study Of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy For Patients With Refractory Or Relapsed Primary CNS Lymphoma (PCNSL) |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | rituximab |
| Enrollment | 12 |
| Start date | May 1, 2004 |
| Primary completion | Mar 1, 2009 |
| Completion | Jun 1, 2010 |
| First posted | Nov 6, 2003 |
| Last update posted | Aug 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: